Introduction
Prompt treatment may dramatically affect the outcome of lupus nephritis (Cathcart et al., 1976; Levinsky, Cameron and Soothill, 1977; Dosa et al., 1978) . It is therefore crucial to distinguish it from idiopathic glomerulonephritis as early as possible but this may be difficult especially in the absence of extrarenal manifestations of systemic lupus erythematosus (SLE), since renal biopsy appearances are not diagnostic (Simenoff and Merrill, 1964) . The detection of circulating antinuclear factor (ANF) is widely used as a screening test for SLE and while false positive results are common (Svec and Veit, 1967; Bartholomew, 1974; Burnham, 1972; AlarconSegovia, 1976 ), the test is so sensitive that some authorities suggest that a single negative ANF excludes the diagnosis (Hughes, 1974; Friou, 1972) .
Eleven patients were seen who developed glomerulonephritis and in whom the ANF was initially negative but subsequently became positive. In 4, a diagnosis of SLE has now been made.
The patients
Details of the 11 patients are given in (Friou, 1972) . A delay in the appearance of an ANF was due to steroids in only one of these patients (Case 1). Of the other 3, it became positive as the clinical illness remitted in 2 and only during a second exacerbation in one.
Case 5 has another connective tissue disease, a frequent cause of a positive ANF (Bartholomew, 1974) . In this patient, the delayed appearance of the ANF may have been due to long-term steroid therapy. IgG paraprotein with specific anti-DNA antibody activity has been reported (Cryer and Kissane, 1976) and it is probable that the paraprotein detected in Case 6 was acting as an antinuclear factor. Penicillamine and methyldopa are known to cause lupus syndromes (Elsas et al., 1971; Feltkamp, Dourhout-Mees and Nieuwenhuis, 1970) and these drugs appear to be responsible for the late appearance of an ANF in 4 of the patients (Cases 7, 8, 9 and 10). The immunochemical disturbance may persist after withdrawal of the drug, as in Cases 7 and 10 (Alarcon-Segovia et al., 1967). The pattern of staining of the ANF and titre of antibody are said to be helpful in distinguishing lupus and non-lupus patients (Husain et al., 1974; Epstein, 1977) ; this was not the case in the present patients although the antibody was not titrated.
The renal biopsies of patients with renal manifestations of SLE show a wide variety of changes on light microscopy Rothfield, 1977) but none of the present patients showed the abnormalities said to be particularly associated with the disease, haematoxyphil bodies, segmental fibrinoid necrosis, hyaline thrombi and 'wire loops' (Pollak, Pirani and Schwartz, 1964; Dujovne et al., 1972; Pollak and Pirani, 1974; Meadows, 1978) . The 4 patients in whom SLE was diagnosed illustrate the range of appearances possible in the disease. Renal immunofluorescence is reported to be invariably positive in SLE. IgG is the usual localizing immunoglobulin although both IgM and IgA are often found (Koffler et al., 1969; Pollak and Pirani, 1974; Cavallo, Cameron and Lapenas, 1977; Cameron et al., 1977) and no specific patterns of immunoglobulin deposition may be considered specific for the condition. Electron microscopy may also reveal a wide variety of changes and electrondense deposits may be seen in any location (Comerford and Cohen, 1967; Dujovne et al., 1972; Pollak and Pirani, 1974; Baldwin et al., 1977) . While subepithelial, intramembranous, subendothelial and mesangial electron-dense deposits were all present together in biopsies from 2 of the lupus patients (Cases 1 and 3), they were also present in a non-lupus patient (Case 9). The changes seen on electron microscopy in Case 8 were attributable to hypertension, and the Bence-Jones tubular casts in Case 6 accord with the finding of a monoclonal immunoglobulin in the patient's serum. Detailed examination of renal biopsy material and the study of the evolution of the renal lesion on repeated biopsies has not helped distinguish between the lupus and non-lupus patients. (1977) have reported 7 patients with lupus nephritis in whom a persistently negative ANF was associated with positive anti-DNA antibodies. In common with others, the present authors have found anti-DNA antibody and serum complement levels valuable in making a diagnosis (Davis et al., 1973; Cameron et al., 1976) . While isolated abnormal levels occurred in the non-lupus patients, the association of a positive ANF, high anti-DNA antibody, and low complement levels have usually occurred in those in whom lupus has been diagnosed. The late appearance of a positive ANF in the absence of other clinical or laboratory evidence of disease activity should suggest a cause other than SLE. Cohen and Canosa (1972) have commented that lupus patients frequently fail to fulfill the American Rheumatism Association criteria for the diagnosis at first presentation and this has been the experience of the present authors. A single negative ANF must not be accepted as excluding SLE. Repeated estimations are required and, when accompanied by other immunological measurements, may make earlier diagnosis possible. As therapy for severe renal lupus improves, this becomes increasingly desirable. 
